GlassScriptPhysician profile
James G Kohlroser
NPI 1508884842
$8,898.97
in general payments reported to CMS, 2019-2025
38 companies · $2,362 in 2025
The $2,362 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,066 · 2020: $136 · 2021: $667 · 2022: $979 · 2023: $1,404 · 2024: $2,284 · 2025: $2,362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,951 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,950.97 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,765.59 | 2020-2025 | |
| Boston Scientific Corporation | $1,177.53 | 2019-2023 | Watchman Access System |
| Janssen Biotech, INC. | $814.27 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $642.56 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $604.09 | 2021-2025 | Xifaxan |
| Organon LLC | $412.48 | 2023-2025 | Hadlima, Renflexis |
| Intercept Pharmaceuticals, INC. | $258.61 | 2020-2024 | Ocaliva |
| Ardelyx, INC. | $235.74 | 2023-2025 | Ibsrela |
| Celgene Corporation | $228.94 | 2019-2024 | Zeposia |
| Daiichi Sankyo INC. | $225.31 | 2024-2025 | Injectafer |
| Phathom Pharmaceuticals, INC. | $218.22 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $208.90 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $189.99 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $183.77 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $182.50 | 2021-2025 | Entyvio |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $181.69 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $165.13 | 2020-2024 | Dificid |
| Redhill Biopharma INC. | $132.68 | 2020-2024 | Talicia |
| Qol Medical, LLC | $131.47 | 2021-2024 | Sucraid |
| Gilead Sciences, INC. | $122.07 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $117.56 | 2024 | Terlivaz |
| Exact Sciences Corporation | $84.88 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $60.00 | 2024-2025 | Omvoh |
| Intra-Sana Laboratories | $58.75 | 2021-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Vivus LLC | $57.07 | 2025 | Pancreaze, Qsymia |
| Evoke Pharma, INC. | $55.63 | 2022-2023 | Gimoti |
| Ferring Pharmaceuticals INC. | $53.16 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.75 | 2023 | Cyltezo |
| Alnylam Pharmaceuticals INC. | $40.95 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $39.04 | 2024-2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $36.47 | 2021-2022 | |
| Stryker Corporation | $26.98 | 2023 | Stryker |
| Cumberland Pharmaceuticals, INC. | $25.30 | 2024 | Kristalose |
| Melinta Therapeutics, LLC | $24.89 | 2024 | Rezzayo |
| Sandoz INC. | $24.69 | 2023 | Hyrimoz |
| Novo Nordisk INC | $22.91 | 2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $22.58 | 2022 | |
| Alfasigma USA, INC. | $20.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kohlroser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.